Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma
about
Novel agents in the treatment of multiple myeloma: a review about the futureCarfilzomib and the cardiorenal system in myeloma: an endothelial effect?Risk stratification, treatment selection, and transplant eligibility in multiple myeloma: a qualitative study of the perspectives and self-reported practices of oncologists.A practical review on carfilzomib in multiple myeloma.Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes.Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics.Carfilzomib-containing combinations as frontline therapy for multiple myeloma: A meta-analysis of 13 trials.Spasmogenic Effects of the Proteasome Inhibitor Carfilzomib on Coronary Resistance, Vascular Tone and Reactivity.Effect of pomalidomide on relapsed/refractory multiple myeloma: a systematic review and meta-analysis.Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis.Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis.An overview of the role of carfilzomib in the treatment of multiple myeloma.Cardiovascular adverse events in modern myeloma therapy - incidence and risks. A review from European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)Carfilzomib for treating myeloma
P2860
Q26745924-015FC15A-C918-4ECA-A24C-2EF5CA4855A8Q36548064-83C54F9B-308E-475E-BEAF-F265E948C066Q37524970-D7F2EE4D-FB65-4E23-9F37-1634BC0AB4CAQ38740271-C97DBC85-734B-4458-AFF0-849C1B068C20Q38756800-45422F69-A0BF-4B52-9A7C-CFDFB3A775BEQ39138108-5B7B4403-0A1D-450B-B9EA-5C0F29CA5A5CQ39177792-6B3FBCCA-5716-4A13-9942-508ACFD316FCQ39234159-A9B013BC-AE3B-402B-9762-678307B3C864Q40293560-FC80BC37-8CF6-4004-AD08-1515C0270133Q41040725-ECDF0172-ABC8-4B91-996A-FEBEA46D58F6Q41396044-E00CCE62-E5B7-4AE4-8FF5-DE014E25A2AEQ47236245-F566AE55-8C5A-45F9-8E42-832CBD7291D8Q48666333-B60C0416-AAA2-4319-8EA9-0E04909FDC1CQ50035012-3623EA85-9F6B-4B05-BB3F-3D0F933E9E13Q56362782-F60F19F2-3EC9-4691-85ED-7EC4AB4AE5E6Q57904173-812B3C04-F53D-45C1-BE13-B9409022C1FA
P2860
Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Phase Ib/II trial of CYKLONE ( ...... e) for newly diagnosed myeloma
@ast
Phase Ib/II trial of CYKLONE ( ...... e) for newly diagnosed myeloma
@en
type
label
Phase Ib/II trial of CYKLONE ( ...... e) for newly diagnosed myeloma
@ast
Phase Ib/II trial of CYKLONE ( ...... e) for newly diagnosed myeloma
@en
prefLabel
Phase Ib/II trial of CYKLONE ( ...... e) for newly diagnosed myeloma
@ast
Phase Ib/II trial of CYKLONE ( ...... e) for newly diagnosed myeloma
@en
P2093
P2860
P356
P1476
Phase Ib/II trial of CYKLONE ( ...... e) for newly diagnosed myeloma
@en
P2093
A Keith Stewart
Angela Mayo
Craig B Reeder
Edward N Libby
Francis Buadi
Joseph R Mikhael
Katherine Gano
Luciano J Costa
P Leif Bergsagel
Sravan K Nagi Reddy
P2860
P304
P356
10.1111/BJH.13296
P407
P50
P577
2015-02-13T00:00:00Z